Last checked at 30 Jul 2009 07:30
For release: 30 July 2009
Epistem Plc ("Epistem" or "the Company")
Pre-Close Trading Update
Epistem Plc (AIM: EHP), the rapidly growing biotechnology company with adult epithelial stem cell expertise in oncology, gastrointestinal and dermatological diseases, announces a pre-close trading update ahead of its final results for the year ending 30th June 2009.
Trading over the year has been strong and in line with market expectations and we expect to report a maiden profit after tax due in part to a prior year tax credit.
The Company expects to release its final results for the year ended 30th June 2009 on Tuesday 6th October 2009 and intends to hold an analyst meeting on the day.
For further information please contact:
| Epistem Plc | |
| Matthew Walls, Chief Executive Officer | +44 161 606 7258 |
| John Rylands, Chief Financial Officer | |
| | |
| Piper Jaffray | |
| Nominated Adviser: Neil Mackison/James Steel | +44 203 142 8700 |
| Corporate Broking: Jamie Adams | |
| | |
| De Facto Communications | |
| Mike Wort/Anna Dunphy | +44 207 861 3838 |
| | |
Notes for Editors
Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which includes the gastrointestinal tract, skin, hair follicles, breast and prostate. Epistem does not conduct research in the areas of embryonic stem cells or stem cell transplantation.